PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Anakinra

Drugs in development · updated 30 October 2026

Anakinra: clinical trials and development status

Other names and codes: KINERET

FDA verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 8 March 2002

As of 30 October 2026 Anakinra is in 26 active clinical trials (recruiting or ongoing, phases I–III) for 50 diseases. The most advanced phase is III.

26Active trials
IIIMost advanced phase
50Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Anakinra and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 50 diseases.

DiseaseMost advanced phaseActive trialsReference trial
COVID-19III3NCT04381936
InflammationIII3NCT07371689
Arthritis, JuvenileIII2NCT05814159
Community-acquired pneumoniaIII2NCT04381936
PneumoniaIII2NCT04381936
Adult-onset Still's diseaseIII1NCT05814159
Familial Mediterranean feverIII1NCT06336733
InfluenzaIII1NCT02735707
Lung diseaseIII1NCT02735707
Mucocutaneous Lymph Node SyndromeIII1NCT04656184
MyocarditisIII1NCT07371689
Post-Acute COVID-19 SyndromeII–III1NCT05926505
Respiratory diseaseIII1NCT02735707
Respiratory tract infectionIII1NCT02735707
Status epilepticusIII1NCT07281027
Ankylosing spondylitisII1NCT07138898
B-cell lymphomaII1NCT04148430
Bronchopulmonary dysplasiaII1NCT07254000
Burkitt lymphomaII1NCT04148430
Chronic kidney failureII1NCT07580079
Cytokine release syndromeII1NCT05611710
Dengue feverII1NCT05611710
DermatomyositisII1NCT07138898
Giant cell arteritisII1NCT07138898
Glucose metabolism diseaseII1NCT07580079
Granulomatosis with polyangiitisII1NCT07138898
Heart failureII1NCT05177822
HypoglycemiaII1NCT07580079
Ischemic strokeII1NCT07423975
Macrophage activation syndromeII1NCT05611710

Everything on Anakinra

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch